Literature DB >> 8821067

Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.

K Jellinger1, L Linert, E Kienzl, E Herlinger, M B Youdim.   

Abstract

The presence of 5-Hydroxydopamine (5-OHDA) and 6-Hydroxydopamine (6-OHDA) in the urine of parkinsonian patients on levodopa medication was reported by Andrew et al. (1993). To answer the question about the putative relevance of 6-OHDA endogenously formed in the brain for the pathogenesis of Parkinson's disease (PD), the chemical mechanisms leading to dopamine-coordinative complexes were investigated in vitro. Kinetic studies of the reaction of dopamine (DA) with dioxygen over the pH range 7.0-9.0, where it reacts spontaneously without the necessity of metal-ion analysis, show that stoichiometric amounts of H2O2 are produced. Pink dopaminochrome, another oxidation product, is not stable and further reacts--without the consumption of dioxygen--to form the insoluble polymeric material known as melanin. Based on these results, the in vitro chemistry of the reactions of DA, 5-OHDA, and 6-OHDA in the presence of Fe3+ and dioxygen are studied. A mechanism for the initiation of a chain reaction is suggested by which excess Fe3+ could arise, and its relevance for the degeneration of dopaminergic neurons in PD is discussed. Detailed studies on the release of ferritin bound iron (0.2-1.4 microM Fe3+) by synthetic DA (200 microM) may provide further insight into the pathogenesis of PD, but further studies are warranted to elucidate the molecular basis of this neurodegenerative disorder of the extrapyramidal system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8821067

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  19 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.

Authors:  Hanoch Elkon; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 4.  The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications.

Authors:  George Perry; Lawrence M Sayre; Craig S Atwood; Rudolph J Castellani; Adam D Cash; Catherine A Rottkamp; Mark A Smith
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet.

Authors:  Jill K Morris; Gregory L Bomhoff; John A Stanford; Paige C Geiger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-08-11       Impact factor: 3.619

6.  Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans.

Authors:  Richard Nass; David H Hall; David M Miller; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

7.  The mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons.

Authors:  J Rodriguez-Pallares; J A Parga; B Joglar; M J Guerra; J L Labandeira-Garcia
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

Review 8.  Parkinson's disease: experimental models and reality.

Authors:  Peizhou Jiang; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2017-11-18       Impact factor: 17.088

9.  Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6.

Authors:  E Giaime; C Sunyach; C Druon; S Scarzello; G Robert; S Grosso; P Auberger; M S Goldberg; J Shen; P Heutink; J Pouysségur; G Pagès; F Checler; C Alves da Costa
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

Review 10.  The 6-hydroxydopamine model of Parkinson's disease.

Authors:  Nicola Simola; Micaela Morelli; Anna R Carta
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.